Statin Therapy and Serum Testosterone in Men with Type 2 Diabetes
Fakhraldeen, M., Mostafa, H. (2018). Statin Therapy and Serum Testosterone in Men with Type 2 Diabetes. EKB Journal Management System, 39(1), 281-287. doi: 10.21608/ejhm.2018.16972
Mohammed Fakhraldeen; Huseen Saad Mostafa. "Statin Therapy and Serum Testosterone in Men with Type 2 Diabetes". EKB Journal Management System, 39, 1, 2018, 281-287. doi: 10.21608/ejhm.2018.16972
Fakhraldeen, M., Mostafa, H. (2018). 'Statin Therapy and Serum Testosterone in Men with Type 2 Diabetes', EKB Journal Management System, 39(1), pp. 281-287. doi: 10.21608/ejhm.2018.16972
Fakhraldeen, M., Mostafa, H. Statin Therapy and Serum Testosterone in Men with Type 2 Diabetes. EKB Journal Management System, 2018; 39(1): 281-287. doi: 10.21608/ejhm.2018.16972

Statin Therapy and Serum Testosterone in Men with Type 2 Diabetes

The Egyptian Journal of Hospital Medicine
Article 15, Volume 39, Issue 1, April 2018, Page 281-287  XML PDF (282.54 K)
Document Type: Original Article
DOI: 10.21608/ejhm.2018.16972
View on SCiNiTO View on SCiNiTO
Authors
Mohammed Fakhraldeen1; Huseen Saad Mostafa2
1Faculty of medicine, Mansoura University
2King Fahd hospital, Riyadh, Saudi Arabia
Abstract
There is a high prevalence of hypogonadism in men with type 2 diabetes. Statins could potentially decrease testosterone levels by reducing the availability of cholesterol for androgen synthesis. In this study we compared testosterone levels and hypogonadal symptoms with statin use in men with type 2 diabetes.
PATIENTS AND METHODS
Total testosterone, sex hormone–binding globulin (SHBG), and estradiol were measured by an enzyme-linked immunosorbent assay. Bioavailable testosterone was measured by the modified ammonium sulfate precipitation method. Free testosterone was calculated using Vermeulen's formula. Symptoms of hypogonadism were assessed using the Androgen Deficiency in the Aging Male questionnaire.
RESULTS
Statins were associated with lower total testosterone and a trend toward lower SHBG compared with untreated patients. Bioavailable testosterone, free testosterone, estradiol, and hypogonadal symptoms were not affected. Atorvastatin was associated with reduced total testosterone and a trend toward reduced SHBG compared with no treatment, and there was a dose-response effect with the lowest levels of total testosterone seen in men treated with ≥20 mg atorvastatin .Simvastatin use was not associated with significant reductions in testosterone or SHBG levels.
CONCLUSION
Assessing androgen status using total testosterone in men with type 2 diabetes treated with statins, particularly atorvastatin, may potentially lead to diagnostic error. Levels of bioavailable testosterone or free testosterone are recommended for the assessment of hypogonadism in this group if total testosterone levels are borderline.
 
Keywords
Type 2 DM; testosterone; Hypogonadism; statin therapy
Statistics
Article View: 162
PDF Download: 323